晚期非小细胞肺癌支气管动脉介入治疗研究现状  

Status and progress of bronchial artery interventional therapy for advanced non-small cell lung cancer

作　　者：陈芋屹 樊庆胜[1] 张怡[1] 刘梓燊 杨国旺[1] CHEN Yuyi;FAN Qingsheng;ZHANG Yi;LIU Zishen;YANG Guowang(Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China)

机构地区：[1]首都医科大学附属北京中医医院肿瘤科,北京100010

出　　处：《中国介入影像与治疗学》2020年第6期374-377,共4页Chinese Journal of Interventional Imaging and Therapy

基　　金：国家自然科学基金(81473643,81774039);国家重点研发计划(2018YFC1705101);北京市科学技术委员会资助项目(Z161100000116061);北京市属医院科研培育计划(PZ2018013);北京市优秀人才培养资助青年骨干个人项目(DBYC201804)。

摘　　要：目前传统全身化学治疗对于不可切除、无驱动基因突变且程序性细胞死亡蛋白1配体(PD-L1)阴性的晚期非小细胞肺癌(NSCLC)的疗效已达瓶颈。支气管动脉介入治疗对于晚期NSCLC是较为成熟的局部微创姑息治疗技术,在提高药物浓度、阻断肿瘤血供、减轻全身副反应等方面具有明显优势。本文对支气管动脉介入治疗的作用机制、获益人群特征及临床应用现状进行综述。Nowadays,the curative effect of traditional systemic chemotherapy has been in a dilemma for patients with advanced unresectable non-small cell lung cancer(NSCLC)who are negative for genetic mutations or programmed cell death 1 ligand 1(PD-L1)expressions.Bronchial artery interventional therapy,represented by bronchial artery infusion(BAI)and bronchial artery chemoembolization(BACE),is a mature local treatment for advanced NSCLC which has prominent advantages in several aspects such as improving the concentration of chemotherapeutic drugs,blocking feeding arteries of tumor and reducing systemic adverse reactions.The mechanism,the characteristics of benefiting crowd as well as the current status of bronchial artery interventional treatment were reviewed in this article.

关 键 词：癌 非小细胞肺 化学栓塞 治疗性 

分 类 号：R734.2[医药卫生—肿瘤] R815[医药卫生—临床医学]